4D Molecular Therapeutics, Inc. (FDMT) stock
Close on Nov 12, 2026Market cap $874.46MP/E –Yield –
Earnings
4D Molecular Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of 4D Molecular Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q3 FY2026ended Sep 30, 2026 | Nov 9, 2026Expected | – | – | – | – |
| Q2 FY2026ended Jun 30, 2026 | Aug 13, 2026after the close | $3.80M | +25233.3% | – | Release |
| Q1 FY2026ended Mar 31, 2026 | May 7, 2026after the close | $3.00M | +21328.6% | -$1.01 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 18, 2026after the close | – | – | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 10, 2025before the open | $90.00K | +2900.0% | -$1.01 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 11, 2025before the open | $15.00K | +200.0% | -$0.98 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 8, 2025after the close | $14.00K | -50.0% | -$0.86 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 28, 2025after the close | – | – | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 13, 2024after the close | $3.00K | -100.0% | -$0.79 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 8, 2024after the close | $5.00K | -97.9% | -$0.63 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 9, 2024after the close | $28.00K | -90.6% | -$0.66 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 29, 2024after the close | – | – | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 9, 2023after the close | $20.20M | +3940.8% | -$0.24 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 9, 2023after the close | $239.00K | +19.5% | -$0.77 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 11, 2023after the close | $298.00K | -75.2% | -$0.88 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 15, 2023after the close | – | – | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 9, 2022after the close | $500.00K | -64.3% | -$0.79 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 11, 2022after the close | $200.00K | – | -$0.87 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 12, 2022after the close | $1.20M | – | -$0.82 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 28, 2022after the close | – | – | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 10, 2021after the close | $1.40M | – | -$0.82 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 12, 2021after the close | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 13, 2021after the close | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 25, 2021after the close | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
4D Molecular Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When 4D Molecular Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases 4D Molecular Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
See a number that looks wrong?